Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
Authors
Keywords
-
Journal
Drugs - Real World Outcomes
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-16
DOI
10.1007/s40801-021-00278-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database
- (2021) Maria Antonietta Barbieri et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
- (2020) Stefania Oliva et al. Frontiers in Oncology
- Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
- (2020) Daniel Eiger et al. BRITISH JOURNAL OF CANCER
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
- (2020) Grace M. Choong et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oral mucositis: the hidden side of cancer therapy
- (2020) Claudio Pulito et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- (2019) T Bachelot et al. ANNALS OF ONCOLOGY
- Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
- (2019) Flávia Campos Barcelos et al. Frontiers in Pharmacology
- HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
- (2019) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- Overall Mortality After Diagnosis of Breast Cancer in Men vs Women
- (2019) Fei Wang et al. JAMA Oncology
- Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
- (2019) Maria Antonietta Barbieri et al. Frontiers in Pharmacology
- Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
- (2018) Hans Wildiers et al. LANCET ONCOLOGY
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy
- (2018) Annie Moisan et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study
- (2017) Cristina Scavone et al. Frontiers in Pharmacology
- Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
- (2017) Franziska Paech et al. Frontiers in Pharmacology
- Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis
- (2016) Francesca De Lorenzi et al. ANNALS OF SURGICAL ONCOLOGY
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis
- (2015) Omar Abdel-Rahman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
- (2014) George Dranitsaris et al. BREAST CANCER RESEARCH AND TREATMENT
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
- (2013) David Miles et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems
- (2013) Shanthi N. Pal et al. DRUG SAFETY
- High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production
- (2012) J. N. Thon et al. BLOOD
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Incidence and Outcome of Male Breast Cancer: An International Population-Based Study
- (2011) Hui Miao et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
- (2011) Bing-He Xu et al. Chinese Journal of Cancer
- Structure-Based View of Epidermal Growth Factor Receptor Regulation
- (2008) Kathryn M. Ferguson Annual Review of Biophysics
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started